CL2021002690A1 - Método para preparar formulaciones de péptidos estables - Google Patents

Método para preparar formulaciones de péptidos estables

Info

Publication number
CL2021002690A1
CL2021002690A1 CL2021002690A CL2021002690A CL2021002690A1 CL 2021002690 A1 CL2021002690 A1 CL 2021002690A1 CL 2021002690 A CL2021002690 A CL 2021002690A CL 2021002690 A CL2021002690 A CL 2021002690A CL 2021002690 A1 CL2021002690 A1 CL 2021002690A1
Authority
CL
Chile
Prior art keywords
preparing stable
peptide formulations
stable peptide
preparing
powder formulation
Prior art date
Application number
CL2021002690A
Other languages
English (en)
Inventor
Gregory Nelson Brown
Scoik Kurt Gard Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2021002690A1 publication Critical patent/CL2021002690A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un método mejorado para preparar una formulación en polvo que contiene un péptido. La presente invención también proporciona un método mejorado para preparar una formulación en polvo que contiene glucagón o un análogo de glucagón, en donde dicha formulación en polvo es adecuada para administración nasal.
CL2021002690A 2019-04-26 2021-10-14 Método para preparar formulaciones de péptidos estables CL2021002690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962839246P 2019-04-26 2019-04-26

Publications (1)

Publication Number Publication Date
CL2021002690A1 true CL2021002690A1 (es) 2022-07-08

Family

ID=70554273

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002690A CL2021002690A1 (es) 2019-04-26 2021-10-14 Método para preparar formulaciones de péptidos estables

Country Status (20)

Country Link
US (1) US20220192988A1 (es)
EP (1) EP3958838A1 (es)
JP (2) JP7245926B2 (es)
KR (1) KR20210143253A (es)
CN (1) CN113727700A (es)
AR (1) AR118690A1 (es)
AU (1) AU2020261941B2 (es)
BR (1) BR112021018325A2 (es)
CA (1) CA3134757A1 (es)
CL (1) CL2021002690A1 (es)
CO (1) CO2021014034A2 (es)
EA (1) EA202192475A1 (es)
EC (1) ECSP21079422A (es)
IL (1) IL286426A (es)
MA (1) MA55757A (es)
MX (1) MX2021012852A (es)
PE (1) PE20212368A1 (es)
SG (1) SG11202110413YA (es)
TW (1) TWI771669B (es)
WO (1) WO2020219391A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116718762A (zh) * 2023-06-09 2023-09-08 上海品峰医疗科技有限公司 一种多肽类样本稳定剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
MY160219A (en) 2008-12-15 2017-02-28 Zealand Pharma As Glucagon analogues
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
BR112013032717A2 (pt) * 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
US20130316941A1 (en) 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9018162B2 (en) * 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
FI3258919T4 (fi) * 2015-02-17 2023-02-09 Nasaalinen jauheformulaatio hypoglykemian hoitoon

Also Published As

Publication number Publication date
CN113727700A (zh) 2021-11-30
US20220192988A1 (en) 2022-06-23
PE20212368A1 (es) 2021-12-21
SG11202110413YA (en) 2021-10-28
WO2020219391A1 (en) 2020-10-29
MA55757A (fr) 2022-03-02
TWI771669B (zh) 2022-07-21
KR20210143253A (ko) 2021-11-26
EP3958838A1 (en) 2022-03-02
IL286426A (en) 2021-10-31
MX2021012852A (es) 2021-12-10
TW202108599A (zh) 2021-03-01
JP7245926B2 (ja) 2023-03-24
EA202192475A1 (ru) 2022-01-28
AU2020261941A1 (en) 2021-10-14
JP2023075249A (ja) 2023-05-30
AU2020261941B2 (en) 2023-04-06
CA3134757A1 (en) 2020-10-29
AR118690A1 (es) 2021-10-27
JP2022529614A (ja) 2022-06-23
ECSP21079422A (es) 2021-11-30
BR112021018325A2 (pt) 2021-11-23
CO2021014034A2 (es) 2021-10-29

Similar Documents

Publication Publication Date Title
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
SV2017005515A (es) Formulaciones de polvo nasal para el tratamiento de la hipoglicemia
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
WO2019087083A3 (en) Oral delivery of glp-1 peptide analogs
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2021006969A (es) Ligante peptidico.
PH12018502615A1 (en) Depot formulations
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
ECSP21060917A (es) Formulación de anticuerpos terapéuticos
ECSP21079422A (es) Método para preparar formulaciones de péptidos estables
AU2017370226A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
CL2022001486A1 (es) Formulaciones de anticuerpos anti-pd-l1.
MX2020010085A (es) Formulaciones que contienen péptidos.
MX2020000144A (es) Composicion farmaceutica para administracion nasal.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
CL2022001085A1 (es) Formulación de anticuerpo que contiene crizanlizumab
BR112018006969A2 (pt) derivados de azetidina para formação de imagem de tau
MX2020010928A (es) Una composicion farmaceutica en polvo seco para inhalacion que comprende una hormona tiroidea.
NI202000095A (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
EA202191327A1 (ru) Лекарственные формы терапевтических препаратов от гриппа
EA202092373A1 (ru) Сухая порошкообразная фармацевтическая композиция для ингаляции, содержащая тиреоидный гормон
BR112021026575A2 (pt) Composições farmacêuticas para peptídeos coagonistas de glucagon e glp-1
CY1123966T1 (el) Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας